Literature DB >> 24785612

Early-onset group B streptococcal disease in the United States: potential for further reduction.

Jennifer R Verani1, Nancy L Spina, Ruth Lynfield, William Schaffner, Lee H Harrison, Amy Holst, Stepy Thomas, Jessica M Garcia, Karen Scherzinger, Deborah Aragon, Susan Petit, Jamie Thompson, Lauren Pasutti, Roberta Carey, Lesley McGee, Emily Weston, Stephanie J Schrag.   

Abstract

OBJECTIVE: To describe lapses in adherence to group B streptococcus (GBS) prevention guidelines among cases of early-onset GBS disease in term and preterm neonates and to estimate the potential for further reduction in disease burden under current prevention strategies.
METHODS: We reviewed labor and delivery and prenatal records of mothers of neonates with early-onset GBS disease (aged younger than 7 days with GBS isolated from a normally sterile site) identified at population-based surveillance sites in 2008-2009. We interviewed prenatal care providers about GBS screening practices and obtained relevant laboratory records. We evaluated the data for errors in prenatal screening, laboratory methods, communication of results, and intrapartum antibiotic prophylaxis. Using published data on screening sensitivity and intrapartum prophylaxis effectiveness, we estimated the potential reduction in cases under optimal prevention implementation.
RESULTS: Among 309 cases, 179 (57.9%) had one or more implementation errors. The most common error type in term and preterm case-patients was prenatal screening (80 of 222 [36.0%]) and intrapartum prophylaxis (46 of 85 [54.1%]), respectively. We estimated that under optimal implementation, cases of early-onset GBS disease could be reduced by 26-59% with the largest benefit from a single intervention coming from improved use of intrapartum prophylaxis (16% decrease).
CONCLUSION: Further reduction of early-onset GBS disease burden is possible under current prevention strategies, particularly with improved implementation of antibiotic prophylaxis. However, even with perfect adherence to recommended practices, the decline in cases may be modest. Therefore, novel prevention approaches such as improved intrapartum assays and vaccines are also needed.

Entities:  

Mesh:

Year:  2014        PMID: 24785612     DOI: 10.1097/AOG.0000000000000163

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  21 in total

1.  Modification of the CpsA protein reveals a role in alteration of the Streptococcus agalactiae cell envelope.

Authors:  Hannah M Rowe; Brett R Hanson; Donna L Runft; Qian Lin; Steve M Firestine; Melody N Neely
Journal:  Infect Immun       Date:  2015-02-02       Impact factor: 3.441

2.  Developing a serocorrelate of protection against invasive group B streptococcus disease in pregnant women: a feasibility study.

Authors:  Clara Carreras-Abad; Madeleine Cochet; Tom Hall; Laxmee Ramkhelawon; Asma Khalil; Elisabeth Peregrine; Latha Vinayakarao; Sharmila Sivarajan; Rosol Hamid; Tim Planche; Elizabeth Sheridan; Stephen Winchester; Jane Plumb; Abdelmajid Djennad; Nick Andrews; Kirsty Le Doare; Paul Heath
Journal:  Health Technol Assess       Date:  2019-12       Impact factor: 4.014

3.  Streptococcus agalactiae Strains with Chromosomal Deletions Evade Detection with Molecular Methods.

Authors:  Isabella A Tickler; Fred C Tenover; Scott Dewell; Victoria M Le; Rachel N Blackman; Richard V Goering; Amy E Rogers; Heather Piwonka; Brittney D Jung-Hynes; Derrick J Chen; Michael J Loeffelholz; Devasena Gnanashanmugam; Ellen Jo Baron
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

4.  Racial disparities in intrapartum group B Streptococcus colonization: a higher incidence of conversion in African American women.

Authors:  Melissa H Spiel; Michele R Hacker; Miriam J Haviland; Bethany Mulla; Elizabeth Roberts; Laura E Dodge; Brett C Young
Journal:  J Perinatol       Date:  2019-01-11       Impact factor: 2.521

Review 5.  Current management and long-term outcomes following chorioamnionitis.

Authors:  Clark T Johnson; Azadeh Farzin; Irina Burd
Journal:  Obstet Gynecol Clin North Am       Date:  2014-11-20       Impact factor: 2.844

6.  Group B Streptococcus circumvents neutrophils and neutrophil extracellular traps during amniotic cavity invasion and preterm labor.

Authors:  Erica Boldenow; Claire Gendrin; Lisa Ngo; Craig Bierle; Jay Vornhagen; Michelle Coleman; Sean Merillat; Blair Armistead; Christopher Whidbey; Varchita Alishetti; Veronica Santana-Ufret; Jason Ogle; Michael Gough; Sengkeo Srinouanprachanh; James W MacDonald; Theo K Bammler; Aasthaa Bansal; H Denny Liggitt; Lakshmi Rajagopal; Kristina M Adams Waldorf
Journal:  Sci Immunol       Date:  2016-10-14

7.  Strategies for preventing group B streptococcal infections in newborns: a nation-wide survey of Italian policies.

Authors:  Chryssoula Tzialla; Alberto Berardi; Claudio Farina; Pierangelo Clerici; Alessandro Borghesi; Elsa Viora; Paolo Scollo; Mauro Stronati
Journal:  Ital J Pediatr       Date:  2017-11-02       Impact factor: 2.638

8.  The evidence base for US joint commission hospital accreditation standards: cross sectional study.

Authors:  Sarah A Ibrahim; Kelly A Reynolds; Emily Poon; Murad Alam
Journal:  BMJ       Date:  2022-06-23

9.  Epidemiology of Invasive Early-Onset and Late-Onset Group B Streptococcal Disease in the United States, 2006 to 2015: Multistate Laboratory and Population-Based Surveillance.

Authors:  Srinivas Acharya Nanduri; Susan Petit; Chad Smelser; Mirasol Apostol; Nisha B Alden; Lee H Harrison; Ruth Lynfield; Paula S Vagnone; Kari Burzlaff; Nancy L Spina; Elizabeth M Dufort; William Schaffner; Ann R Thomas; Monica M Farley; Jennifer H Jain; Tracy Pondo; Lesley McGee; Bernard W Beall; Stephanie J Schrag
Journal:  JAMA Pediatr       Date:  2019-03-01       Impact factor: 16.193

10.  Non-haemolytic and non-pigmented group b streptococcus, an infrequent cause of early onset neonatal sepsis.

Authors:  Javier Rodriguez-Granger; Barbara Spellerberg; Daniela Asam; Manuel Rosa-Fraile
Journal:  Pathog Dis       Date:  2015-10-07       Impact factor: 3.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.